Artesunate is one of the recommended treatments for malaria in children. The Centers for Disease Control and Prevention (CDC) recommend artemether-lumefantrine or artesunate-amodiaquine as the first-line treatment for uncomplicated malaria in children in areas where the Plasmodium falciparum parasite is present [3]. The World Health Organization (WHO) also recommends artesunate as the preferred treatment for severe malaria in children and adults [2].

Artesunate is an artemisinin derivative that has been shown to be highly effective in treating malaria. It has a fast onset of action and is well-tolerated by patients [2]. In addition, artemisinin-based combination therapies (ACTs), which include artesunate, are recommended by the WHO as the first-line treatment for uncomplicated malaria [2].

According to Drug Patent Watch, artesunate is available in various formulations, including injectable, oral, and rectal suppository [1]. The choice of formulation depends on the severity of the malaria infection and the patient's ability to take oral medications. Injectable artesunate is recommended for severe malaria, while oral artesunate is recommended for uncomplicated malaria [2].

In conclusion, artesunate is one of the recommended treatments for malaria in children. It is highly effective, well-tolerated, and available in various formulations. However, the choice of treatment depends on the severity of the malaria infection and the patient's ability to take oral medications. It is important to consult with a healthcare provider to determine the most appropriate treatment for each individual case.

Sources:
[1] Drug Patent Watch. Artesunate. Retrieved from https://www.drugpatentwatch.com/p/tradename/ARTESUNATE
[2] World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Retrieved from https://www.who.int/publications/i/item/9789241549127
[3] Centers for Disease Control and Prevention. Malaria Diagnosis & Treatment. Retrieved from https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html